ASCO: Chronic leukemia treatment transformation is cancer advance of the year
the ONA take:
The American Society of Clinical Oncology (ASCO) has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.
Until recently, many patients with CLL had limited effective treatment options for their disease, but four newly Food and Drug Administration (FDA)-approved therapies will significantly alter the prognosis for patients with the disease.
Those drugs include: obinutuzumab, ofatumumab, ibrutinib, and idelalisib. Obinutuzumab and ofatumumab are each to be used in combination with standard chemotherapy for those with previously untreated CLL, while ibrutinib and idelalisib are for relapsed or refractory CLL. For older patients particularly, these new therapies may be their first chance at treatment as other therapies were toxic for many to tolerate.
According to the American Cancer Society, there was estimated to be 15,720 cases of CLL in 2014 and 4,600 deaths from CLL. CLL accounts for approximately one-third of new cases of leukemia and mainly occurs in older adults with the average age of diagnosis being 72 years.
The ASCO has announced that the transformation of treatment for CLL is its Cancer Advance of the Year.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|